Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer Study
Hepatic Impairment
Renal Impairment

Interventions

DRUG: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

Sponsor

Atea Pharmaceuticals, Inc.